» Articles » PMID: 7436358

Radiation Therapy for Brain Metastases

Overview
Journal Ann Neurol
Specialty Neurology
Date 1980 Jun 1
PMID 7436358
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

We treated 183 patients who had brain metastases with whole-brain radiation therapy (RT) and adrenocorticosteroids utilizing a new high-dose radiation protocol. Treatment produced neurological improvement in 135 patients (74%); there was no change in 37 (20%), and deterioration occurred in 11 (6%). Of those patients who improved, two-thirds maintained neurological improvement for the remainder of their lives or for at least nine months, and one-third relapsed. One-third of those who relapsed improved again with steroids or further RT. Clinical improvement paralleled tumor regression on CT scan. Despite the clinical response, median survival was only twelve weeks; 24% lived six months and 8% lived one year. Death resulted from progressive brain disease in 16% of the patients. Two-thirds of the patients died of advancing systemic disease in the setting of stable, improved neurological function. These data suggest that the majority of patients with brain metastases benefit from RT and that systemic cancer, not central nervous system disease, limits the length of life.

Citing Articles

Comparison of single- and multi-isocenter planning with Dynamic WaveArc for multiple brain metastases.

Terabe M, Kamomae T, Taniguchi Y, Ichikawa H, Yamada T, Miyachi T J Radiat Res. 2024; 66(1):74-81.

PMID: 39724931 PMC: 11753834. DOI: 10.1093/jrr/rrae098.


Advances in the Management of Lung Cancer Brain Metastases.

Hockemeyer K, Rusthoven C, Pike L Cancers (Basel). 2024; 16(22.

PMID: 39594735 PMC: 11593022. DOI: 10.3390/cancers16223780.


The safety and efficacy of stereotactic radiosurgery in patients with gastrointestinal cancer brain metastasis: a systematic review and meta-analysis.

Habibi M, Babaei H, Tavani S, Delbari P, Allahdadi A, Rashidi F Neurosurg Rev. 2024; 47(1):851.

PMID: 39549142 DOI: 10.1007/s10143-024-03105-5.


Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies.

Goldman M, Lucke-Wold B, Martinez-Sosa M, Katz J, Mehkri Y, Valisno J Explor Target Antitumor Ther. 2022; 3(5):659-675.

PMID: 36338521 PMC: 9630032. DOI: 10.37349/etat.2022.00106.


End to end comparison of surface-guided imaging versus stereoscopic X-rays for the SRS treatment of multiple metastases with a single isocenter using 3D anthropomorphic gel phantoms.

Bry V, Saenz D, Pappas E, Kalaitzakis G, Papanikolaou N, Rasmussen K J Appl Clin Med Phys. 2022; 23(5):e13576.

PMID: 35322526 PMC: 9121024. DOI: 10.1002/acm2.13576.